A Look at Pharma’s Tech-Driven Transformation in 2024

A Look at Pharma's Tech-Driven Transformation in 2024


The pharmaceutical landscape is undergoing a transformative phase, driven by groundbreaking innovations, disruptive technologies, and a heightened focus on personalized medicine. Despite the challenges posed by the COVID-19 pandemic, the industry has demonstrated remarkable resilience, adapting to the new normal and embracing digital transformation.

The global pharmaceutical manufacturing market is poised for significant growth, projected to exceed $570.01bn in 2024, driven by increasing demand for innovative therapies and rising healthcare expenditures. The key market segments, including oncology, immunology, diabetes, cardiovascular, respiratory, and central nervous system disorders, are expected to witness substantial growth in the coming years.

Pharmaceutical Manufacturing Market 2022 to 2032 (USD Billion)


The pharmaceutical manufacturing market witnessed robust growth of 12% in 2023, reaching $508.48bn in revenues. This surge can be attributed to factors such as the increasing number of prescription drugs, an aging global population, and the growing demand for innovative medicines.

Technological Breakthroughs

The convergence of science and technology is fueling innovation in the pharma industry. Artificial intelligence (AI) and big data analytics are revolutionizing drug discovery, clinical trials, and personalized medicine. The report highlights ten key technological trends that are transforming the pharmaceutical landscape, including:

1. Artificial Intelligence in Pharma:

The application of artificial intelligence (AI) is accelerating drug research and development. AI algorithms analyze massive datasets of genetic and medical information, leading to the identification of new drug targets and the development of more effective therapies. Startups are leveraging AI to address various challenges, such as automating and optimizing production processes, as well as developing successful marketing and post-launch strategies. AI streamlines patient identification for clinical trials, making the process quicker and more cost-effective by scanning electronic health records and unstructured doctors' notes.

2. Big Data & Analytics:

The pharmaceutical industry requires high-performance systems to process the vast amounts of data generated throughout the drug research and development process. Advanced analytical methodologies are transforming historical and real-time data held by pharmaceutical companies into valuable assets for predictive, diagnostic, prescriptive, and descriptive analytics. These pharmaceutical analytics approaches are applied to various types of medical data, including patient records, medical imaging, and hospital data, to gain insights and drive decision-making.

3. Flexible Production:

As market dynamics change, the pharmaceutical sector is exploring novel production methods, such as small batches for precision medicine and single-use bioreactors. These bioreactors eliminate downtime and increase output by removing tasks like cleaning and validation from distinct production phases. New bioreactor systems and continuous production procedures are being developed to meet the growing demand for biopharmaceuticals, reducing energy consumption, increasing productivity, and minimizing waste.

4. Precision Medicine:

Precision medicine is based on the notion of treating each patient as a unique individual. Advances in omics and data analysis are revealing new information on how the human body responds to drugs. This information, combined with innovative production techniques like additive manufacturing, is making personalized medicine a reality. Drug exposure models calculate the pharmacokinetic and pharmacodynamic properties of drugs to determine the appropriate dosage based on age, gender, comorbidities, and other clinical data.

5. Additive Manufacturing:

The demand for precision medicine is forcing pharmaceutical corporations to rethink the production process. Significant research is being conducted to develop powerful 3D printers capable of creating tissues or cells. The pharmaceutical industry utilizes 3D printing for drug development, organ engineering, and regenerative medicine. Additive manufacturing enables the production of medicinal formulations tailored to age or physiology, as well as precise tablets.

6. Blockchain:

Blockchain technology has immense implications for the pharmaceutical sector at all stages of drug development and delivery. Due to the sensitive nature of the data, players in the pharmaceutical sector are often quite discreet about it. Blockchain is being explored to combat the use of counterfeit pharmaceuticals and inferior treatments in the supply chain, which claim thousands of lives each year. Blockchain is a viable tool for tracking and securing the pharmaceutical transaction ecosystem as transactions become more digital.

7. Extended Reality (XR):

Mixed reality (MR), virtual reality (VR), and augmented reality (AR) are enabling visualizations like never before. Pharma entrepreneurs are investigating the use of extended reality technology in pharmaceutical research and manufacturing. Extended reality solutions provide data-rich and relevant real-time location-based engagement among research teams. Human enhancement in pharmaceuticals is becoming a reality thanks to startups developing extended reality devices and technologies.

8. Digital Therapeutics:

Digital therapy uses software to provide evidence-based therapeutic treatments for the prevention, management, and treatment of physical, mental, and behavioral issues. These non-pharmacological, technological solutions can be used alone or in combination with drugs, devices, or therapy. Digital medicines give each individual more control over their health and outcomes, enabling personalized treatment and improved patient convenience.

9. Curative Therapies:

There is a paradigm shift in the treatment of diseases, from disease management to disease cure. Curative therapies, such as cell and gene therapies, are revolutionizing the way we treat chronic diseases and difficult-to-treat conditions by eliminating the need for long-term medications. Gene therapy involves introducing genetic material into cells to correct defective genes or produce a beneficial protein, often using genetically modified viruses as vectors.

These cutting-edge technologies are enabling pharmaceutical companies to optimize processes, enhance efficiency, and develop targeted therapies tailored to individual patient needs.

Emerging Therapies

Latest advancements in emerging therapies, such as oncology, immunology, and rare diseases. The oncology market, in particular, is being revolutionized by innovative approaches like immunotherapy and targeted therapies, with spending in this segment expected to reach $375 billion by 2027.

Top 20 therapy areas in terms of global spending from 2023 – 2027


Moreover, the biotech sector is expected to experience substantial growth, with emerging biopharma companies accounting for a significant portion of the oncology pipeline, indicating the pivotal role of smaller, nimbler firms in driving cutting-edge cancer innovation.

Strategic Imperatives

To capitalize on the growth opportunities and navigate the evolving landscape, the report outlines several strategic imperatives for pharmaceutical and biotech companies:

1. Embracing digital transformation and harnessing new technologies like AI, big data, and automation to accelerate drug discovery and development.

2. Pursuing agile business development strategies, including strategic partnerships, mergers and acquisitions, and venture investments, to access emerging science, talent, and high-potential markets.

3. Developing advanced therapies in cutting-edge areas like oncology, rare diseases, gene therapy, and personalized medicine to address significant unmet needs.

4. Adapting product portfolios and pipelines to diversify from blockbuster drug dependence, optimize non-core assets, and prepare for patent expires.


The pharmaceutical industry is at an inflection point, poised for transformative growth and innovation. Companies that embrace digital transformation, foster agile business strategies, and invest in cutting-edge therapies will be well-positioned to capture a larger share of the market and drive meaningful impact on patient lives.

As the industry continues to evolve, it will be crucial for stakeholders to stay informed, adapt to changing market conditions, and seize opportunities for growth and innovation.


- Amit Kamadollishettaru (Equity Analyst)

For more on Pharma and biotech CLICK HERE


Latest updated blogs

Share this article on:

Shopping cart